BMY250103P62000
- 5.50
- 0.000.00%
Bristol-Myers Squibb Newsroom
Santa Clause Came and Went Without Bringing Gifts | Weekly Buzz
Friday? More Like Grinch Day | Wall Street Today
Santa Claus Came Without Rallying the Troops | Live Stock
Bristol Myers Squibb to Present at J.P. Morgan's 43rd Annual Healthcare Conference
Update: Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
Bristol-Myers Squibb Options Spot-On: On January 2nd, 391.89K Contracts Were Traded, With 617.52K Open Interest
Jefferies Maintains Bristol-Myers Squibb(BMY.US) With Buy Rating, Maintains Target Price $70
Jefferies Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb's (NYSE:BMY) Investors Will Be Pleased With Their 2.4% Return Over the Last Five Years
Bristol-Myers Squibb To Go Ex-Dividend On January 3rd, 2025 With 0.62 USD Dividend Per Share
Brand Prescription Drugs to Rise an Average 4.5% in 2025
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Peering Into Bristol-Myers Squibb's Recent Short Interest
Market Chatter: Drug Companies to Raise Prices on 250 Branded Drugs in 2025
Oncology Pharmaceuticals Market Research 2024-2029, Profiles of Major Players - Bristol-Myers Squibb, Merck & Co, F. Hoffmann-La Roche, Johnson & Johnson, and AstraZeneca
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Is Bristol-Myers Squibb Co. (BMY) the Best Stock for 10 Years?
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Bristol-Myers Squibb's Patent Expansion Plan May Run Into Regulator Trouble
Brain Tumor Therapeutics Global Research Business Report 2024-2030 Featuring Profiles of Market Leaders Including AstraZeneca, Bristol-Myers Squibb, DelMar Pharmaceuticals - ResearchAndMarkets.com